The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances

Hemodialysed Patients With Impaired Liver Enzymes Clinical Trial

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01054664
• Other study ID #: nephrop003
• Status: Unknown status
• Phase: N/A
• First received: January 21, 2010
• Last updated: January 21, 2010
• Start date: February 2010

Study information

• Verified date: January 2010
• Source: Meir Medical Center
• Contact: Eleonora Plotkin, MD
• Phone: 972 9 7472517
• Email: nora.plotkin[@]clalit.org.il
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To assess the incidence of occult hepatitis C virus in hemodialysed patients with mild impairment of liver enzymes

Description:

occult hepatitis C virus will be checked in monocytes of hemodialyzed patients with permanent mild impairment of liver enzymes This population has no evidence of hepatitis B or C according to standard laboratory tests (HVC antibodies,HCV PCR, hepatitis B antibodies) Hepatitis C virus RNA will be performed in peripheral blood mononuclear cells of hemodialysed patients

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 30
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hemodialysed patients with impaired liver enzymes

Exclusion Criteria:

• hepatitis B and C positive

Related Conditions & MeSH terms

• Hemodialysed Patients With Impaired Liver Enzymes

Locations

Country	Name	City	State
Israel	Plotkin Eleonora	Kfar Saba

Sponsors (1)

Lead Sponsor	Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel,